Hydroxy tipelukast
Hydroxy tipelukast (Compound MN-002), the metabolite of Compound MN-001, is an orally active phenoxyalkylcarboxylic acid. Hydroxy tipelukast inhibits liver steatosis, lobular inflammation, hepatic ballooning, and hepatic scarring, and reduces liver hydroxyproline levels. Hydroxy tipelukast is promising for research of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [1].
Product Specifications
CAS Number
[1027597-04-1]
UNSPSC
12352005
Target
Drug Metabolite
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease; Inflammation/Immunology
Smiles
O=C(CCCOC1=C(CCC)C(OCCCSC2=CC=C(C(O)=C2CCC)C(C)=O)=CC=C1C(C)O)O
Molecular Formula
C29H40O7S
Molecular Weight
532.69
References & Citations
[1]Kazuko Matsuda. Method of treating liver disorders. US20140155484A1. 2015-02-24.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ST3GAL4 (STZ, SAT3, CGS23, SIAT4, NANTA3, SIAT4C, ST3GalIV, CMP-N-Acetylneuraminate-Beta-Galactosamide-Alpha-2,3-Sialyltransferase 4) discontinued
ST3GAL4 (STZ, SAT3, CGS23, SIAT4, NANTA3, SIAT4C, ST3GalIV, CMP-N-Acetylneuraminate-Beta-Galactosamide-Alpha-2,3-Sialyltransferase 4) discontinued
SPACA5B, NT (SPACA5, LYZL5, SPACA5A, Sperm acrosome-associated protein 5, Lysozyme-like protein 5, Sperm-specific lysozyme-like protein X) (MaxLight 490) discontinued
